Format

Send to

Choose Destination
Drug Discov Today. 2011 Apr;16(7-8):325-31. doi: 10.1016/j.drudis.2011.02.008. Epub 2011 Feb 17.

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.

Author information

1
Cancer Institute of New Jersey, Department of Pharmacology, UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.

Abstract

The mTOR signaling pathway is dysregulated in ∼50% of all human malignancies and is a major cancer drug target. Although rapamycin analogs (rapalogs) have shown clinical efficacy in a subset of cancers, they do not fully exploit the antitumor potential of mTOR targeting. Because the mTOR kinase domain is important for rapamycin-sensitive and -insensitive functions, mTOR catalytic inhibitors have been developed recently as the second generation of anti-mTOR agents. Importantly, they have shown marked improvement of antitumor activity in vivo and in vitro. This review will detail the potential therapeutic value and issues of these novel antineoplastic agents, with emphasis placed on those that have already entered clinical trials.

PMID:
21333749
PMCID:
PMC3073023
DOI:
10.1016/j.drudis.2011.02.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center